Middle East Pharmaceutical Industries Company

SR 63.95As of Sun 8 Nov 2026, 12:00 UTC
Tadawul:4016Healthcare
Country Saudi Arabia
PE (Fwd) •••
TSR 3Y CAGR (14.61%)
Div yield 2.16%
ROE 26.12%
Medical (Pharmaceuticals)
Beta (5Y) 0.47
PE TTM 20.63
TSR TTM (16.33%)
Mkt cap SR 2.238B
ROIC 22.82%
SE Grade™
Value
Quality
Moat
Consensus
Reference
SR 65
1.92%
(84.92%)
Hold 8|3|5|8|4
4Q25
1Q26
2Q26
3Q26
Earnings per shareSR
1.37
1.31
1.34
1.35
13.07%
1.52%
0.25%
(6.48%)
RevenueSR M
291.3
292.0
289.6
301.2
17.83%
16.48%
8.99%
8.50%
Peers (US$623.6M)
Cap (US$)
PE
3.324B
15.14x
874.1M
17.42x
65.44M
35.24x
581.2M
10.67x
Capital
TTM
5Y
10Y
Leveragex
1.314
—
—
EBIT/Intx
1.364
0.577
0.586
Own earn%
28.82
55.55
44.57
Sh yield%
22.92
28.13
33.70
Owners
Insiders/Inst%
14.15
79.15
Short interest%
5.23
SBC / revenue%
2.19
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
4
Op margin range%
4–12
$1 testx
—
Incr. ROIC%
53